LAUSR

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, where the risk of its development is always multifactorial. Human interleukin-6 (IL-6) is a pro-inflammatory cytokine that plays a crucial role in the regulation of immune response and defense against viral infection; it was hypothesized that this cytokine may participate in the process of liver damage. The aim of our study was to investigate IL-6-572 C/G gene polymorphism in patients with HCC as compared with healthy controls in an Egyptian population, in order to see if there is a significant association between IL-6 gene polymorphism and susceptibility to HCC development. A total of 165 subjects divided into 55 HCV, 60 HCC, and 50 healthy subjects were enrolled in the study for evaluation. Genomic DNA was extracted from the peripheral blood, and genotyping was performed using RT-multiplex PCR (real-time multiplex polymerase chain reaction) methodology. G/C, G/G, and C/C frequencies in HCV patients were 16.4, 78.2, and 5.5%, respectively; furthermore, the frequencies were 18.3, 75.0, and 6.7% in HCC patients, and 28.0, 62.0, and 10.0% in the control group, respectively. The frequencies of G and C alleles in HCV patients were 86.4 and 13.6% and in HCC patients were 84.2 and 15.8% while in the control group, the frequencies were 76.0 and 24.0%, respectively. There was no significant difference between the studied groups regarding G/C, G/G, and C/C frequencies or G and C allele’s frequencies. IL-6-572 promoter gene polymorphism is neither associated with HCV infection nor with development of HCC. Further studies including bigger sample size are suggested.